Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05087953
Other study ID # SDC 5045/20/074
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 2022
Est. completion date July 2023

Study information

Verified date October 2021
Source University of Sao Paulo General Hospital
Contact Bruno VK Bueno, MD
Phone +55(11)98187-7226
Email vazkerges@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Transthyretin amyloidosis exhibits a variety of possible phenotypes, the hereditary neurological form being the most commonly found and studied (familial amyloidotic polyneuropathy or FAP), which can present from oligosymptomatic patients to patients with peripheral sensorimotor polyneuropathy of varying degrees and dysautonomia. Although a specific mutation usually causes a specific phenotype, that is, with a predominantly cardiac or preferential neurological profile, with the increase in the number of diagnosed cases, an overlapping of clinical presentations has been observed. The assessment of the autonomic profile in individuals with familial amyloidotic cardiomyopathy (FAC) has not been well studied, and it is not known whether patients with an exclusively cardiac profile of the disease may present dysautonomia or whether even mutation carriers without cardiac involvement may exhibit it. In this study, the autonomic profiles of patients with familial amyloidotic heart disease will be compared with the profiles of patients who have mutations but without established heart disease and healthy individuals (control group).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date July 2023
Est. primary completion date January 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - FAC group: patients with familial familial amyloidotic cardiomyopathy (FAC). - Non-FAC group: patients with transthyretin gene mutations who do not have FAC. - Control group: healthy, asymptomatic individuals without comorbidities and without transthyretin gene mutations. - Agreement and signing the informed consent form. Exclusion Criteria: -

Study Design


Intervention

Diagnostic Test:
Head-Up Tilt table test
Autonomic response assessment in the orthostatic head up tilt test.
Heart Rate Variability
Assessment of heart rate variability on 24-hour Holter monitoring..

Locations

Country Name City State
Brazil University of Sao Paulo Medical School - The Heart Institute Sao Paulo
Brazil Fabio Fernandes São Paulo
Brazil Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Sao Paulo

Sponsors (2)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital Fleury

Country where clinical trial is conducted

Brazil, 

References & Publications (4)

Cruz MW, Foguel D, Berensztejn AC, Pedrosa RC, Mundayat R, Ong ML; THAOS Investigators. The demographic, genetic, and clinical characteristics of Brazilian subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey. Amyloid. 2017 Mar;24(sup1):103-104. doi: 10.1080/13506129.2017.1291423. — View Citation

Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid. 2012 Jun;19 Suppl 1:65-7. doi: 10.3109/13506129.2012.673183. Epub 2012 Apr 12. — View Citation

Queiroz MC, Pedrosa RC, Berensztejn AC, Pereira Bde B, Nascimento EM, Duarte MM, Pereira-Junior PP, Cruz MW. Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients. Arq Bras Cardiol. 2015 Nov;105(5):503-9. doi: 10.5935/abc.20150112. Epub 2015 Sep 8. English, Portuguese. — View Citation

Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010 Jul;7(7):398-408. doi: 10.1038/nrcardio.2010.67. Epub 2010 May 18. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Autonomic response profile of patients with FAC. To compare the autonomic profile by analyzing the heart rate variability on 24 hours Holter monitoring, the patterns of chronotropic and pressure response and the valsalva maneuver in the tilt table test of patients with FAC, with individuals with mutations of the transthyretin gene without FAC and in healthy individuals. 6 months
Secondary Correlation between dysautonomia and electrophysiological cardiac disturbances. Evaluate the relationship of dysautonomia with atrioventricular, intraventricular, interventricular conduction disturbances, presence of late potentials in the high-resolution electrocardiogram and occurrence of supraventricular and ventricular arrhythmias on Holter monitoring. 6 months
Secondary Correlation between dysautonomy and structural cardiac alterations. Evaluate the relationship of dysautonomia changes with cardiac structural changes assessed by strain echocardiography. 6 months
See also
  Status Clinical Trial Phase
Completed NCT00001329 - Study of Norepinephrine Levels and Sympathetic Nervous System Activity N/A
Completed NCT00001147 - Blood Sampling for Neurochemical and Genetic Testing N/A
Recruiting NCT04614532 - Recognizing Pain Intensity in Alzheimer's Disease N/A
Completed NCT06095635 - Acute Influence of Resveratrol Supplementation and Beet Extract in Recovery After Exercise in Coronary Paths N/A
Completed NCT03142373 - Effect of CV4 and Rib Raising Techniques on Autonomic Balance N/A
Recruiting NCT06274658 - The Effects of an Acute High-intensity Exercise on Heart and Brain Function in People With Spinal Cord Injury
Completed NCT05325879 - Relationship of Cervical Region Tension With Vagal Function N/A
Recruiting NCT05212129 - Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome N/A